文献速递胸部肿瘤

局限性非小细胞肺癌中不同肿瘤浸润淋巴细胞特征与临床结局相关

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2021-10-13

研究前瞻性收集150例局限性NSCLC患者的新鲜肿瘤及癌旁组织,整合高维流式细胞术与多组学数据。虽TIL浸润程度或单一亚群单独无显著预后价值,但高维流式数据整合识别出两种免疫类型(IM1和IM2),可独立于临床特征预测无复发生存。IM2与不良预后相关,IM1与良好预后相关,并在TCGA数据中验证。

要点

  • TIL浸润总量或单一T细胞亚群单独不显著预测局限性NSCLC预后。
  • 高维流式整合识别IM1和IM2两种免疫类型,可独立预测无复发生存。
  • IM2为不良预后免疫类型,IM1为良好预后免疫类型。

核心结论

  • 局限性NSCLC中浸润T细胞数量与生存无关,但TIL免疫类型具有预后相关性。
  • 整合高维流式细胞术数据识别的免疫类型可独立于临床特征预测无复发生存。

研究设计与样本

  • 前瞻性收集150例局限性NSCLC患者的新鲜肿瘤及癌旁正常组织。
  • 采用高维流式细胞术表征TIL,并整合多重免疫荧光、T细胞受体测序、外显子测序、RNA测序、靶向蛋白质组学及临床病理特征。
  • 研究结果在癌症基因组图谱(TCGA)患者肿瘤中验证。

主要发现

  • TIL浸润程度或特定TIL亚群单独均未显示显著预后价值。
  • 高维流式细胞术数据整合识别出两种主要免疫类型(IM1和IM2),可预测无复发生存且独立于临床特征。
  • IM2与不良预后相关,特征为存在增殖性TIL表达CD103、PD-1、TIM-3和ICOS。
  • IM1与良好预后相关,特征为丰富表达溶细胞酶的CD8+ T细胞、不表达抑制性受体的CD4+ T细胞、B细胞浸润增加及三级淋巴结构。
  • B细胞浸润增加与良好预后相关,B细胞和T细胞均高的肿瘤患者预后最佳。

关键数值与推荐

  • IM2特征:增殖性TIL表达CD103、PD-1、TIM-3和ICOS,与不良预后相关。
  • IM1特征:CD8+ T细胞表达溶细胞酶、CD4+ T细胞不表达抑制性受体、B细胞浸润增加及三级淋巴结构,与良好预后相关。

临床怎么用

  • TIL免疫类型(IM1/IM2)可能为局限性NSCLC预后分层提供信息。
  • B细胞和T细胞浸润均高的肿瘤患者预后最佳,提示联合评估B细胞与T细胞浸润的价值。
  • TIL免疫类型可能指导临床治疗策略的制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established. PATIENTS AND METHODS: Fresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features. RESULTS: While neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8+ T cells expressing cytolytic enzymes, CD4+ T cells lacking the expression of inhibitory receptors, and increased levels of B-cell infiltrates and tertiary lymphoid structures. While increased B-cell infiltration was associated with good prognosis, the best prognosis was observed in patients with tumors exhibiting high levels of both B cells and T cells. These findings were validated in patient tumors from The Cancer Genome Atlas. CONCLUSIONS: Our study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Federico L, McGrail DJ, Bentebibel SE, et al. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2021. PMID: 34653632. doi:10.1016/j.annonc.2021.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。